IL2RA and type 1 diabetes mellitus: While low-dose IL-2 can safely expand/activate circulating Tregs, leading to clinical benefits in patients with GVHD or autoimmune HCV vasculitis, it was necessary to establish whether a therapeutic response may be achieved in the context of the alterations in the IL-2/IL-2R signaling pathway, which could suggest potential resistance of T1D patients to low-dose IL-2.